Q3 beat; promising growth across the key offerings
30/10/24 -"bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance remained unchanged, investors rejoiced at the ..."
Pages
64
Language
English
Published on
30/10/24
You may also be interested by these reports :
05/03/26
Elekta’s Q3 profitability exceeded consensus expectations. Organic sales growth was recorded in EMEA and APAC, while the Americas exhibited weakness. ...
05/03/26
Amplifon reported another quarterly performance miss, with both sales and profitability falling short of the company-compiled consensus. Although the ...
04/03/26
We appreciate Clariane’s stronger-than-expected deleveraging and consider the 2026 targets easily achievable. However, the thin but consensus-beating ...
03/03/26
Given the company’s more tangible operational normalisation and earlier-than-expected exit from the accelerated safeguard plan, incorporating ...